| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441710 | European Journal of Cancer | 2015 | 7 Pages |
Abstract
Results of this pooled analysis provide evidence of safety and effectiveness of second-line everolimus in routine clinical use and support everolimus as a standard of care for VEGF-refractory patients with mRCC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Laurence Albiges, Ulrich Kube, Jean-Christophe Eymard, Manuela Schmidinger, Aristotelis Bamias, Nadia Kelkouli, Bernhard Mraz, Styliani Florini, Gernot Guderian, Agnese Cattaneo, Lothar Bergmann,